Conneqt Health Limited has released a press release.
FY2016 results
Filed with ASX ·
On 6ix: 6ix.com/news/fy2016-results
6ix hasn’t read this filing yet.
Earlier from Conneqt Health
- Large national plan to reimburse SphygmoCor test
- $0.6 million pharmaceutical trial extension
- SphygmoCor selected for US publicly funded study
- US$1.1 million pharmaceutical contract
- Patent granted in USA
Later from Conneqt Health
- Leading research team highlights role of SphygmoCor
- AtCor completes share placement
- Positive Novartis drug trial using SphygmoCor XCEL
- Tax refund
- Study Finds Central Aortic Waveform Improves HF Treatment
Follow Conneqt Health into a list and get an email when it puts out news.
Follow Conneqt Health